Blocking ITGA5 potentiates the efficacy of anti‐PD‐1 therapy on glioblastoma by remodeling tumor‐associated macrophages
Abstract Background Glioblastoma (GBM) is largely refractory to antibodies against programmed cell death 1 (anti‐PD‐1) therapy. Fully understanding the cellular heterogeneity and immune adaptations in response to anti‐PD‐1 therapy is necessary to design more effective immunotherapies for GBM. This s...
Saved in:
Main Authors: | Rongrong Zhao, Ziwen Pan, Jiawei Qiu, Boyan Li, Yanhua Qi, Zijie Gao, Wei Qiu, Weijie Tang, Xiaofan Guo, Lin Deng, Gang Li, Hao Xue |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-06-01
|
Series: | Cancer Communications |
Subjects: | |
Online Access: | https://doi.org/10.1002/cac2.70016 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Extraction of Exosomes from Glioblastoma Multiforme Patients’ Blood Plasma
by: I. F. Gareev, et al.
Published: (2019-11-01) -
Glycosylation Gene Signatures as Prognostic Biomarkers in Glioblastoma
by: Tong Zhao, et al.
Published: (2025-07-01) -
Analysis and Functional Significance of TRAP1 in Glioblastoma
by: I. F. Gareev, et al.
Published: (2025-07-01) -
Homologous tumor cell exosome-based drug delivery system co-delivering temozolomide and resveratrol for orthotopic glioblastoma therapy
by: Xuemei Wang, et al.
Published: (2025-12-01) -
<i>PD-L1</i> and <i>PD-L2</i> gene expression in human glioblastoma cells resistant to chemo- and radiotherapy
by: A. A. Pinevich, et al.
Published: (2023-06-01)